Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edi Brogi

Showing results (91-100 of 214) with videos related to

Pageof 22
Sort By:
Cancer|March 26, 2003
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutationsNoah D Kauff, Edi Brogi, Lauren Scheuer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 14, 2021
Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scannersAbeer M Salama, Matthew G Hanna, Dilip Giri, et al.
Cancer Research|May 19, 2006
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanismKotha Subbaramaiah, Louise R Howe, Elisa R Port, et al.
Cell|September 3, 2013
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stromaXiang H-F Zhang, Xin Jin, Srinivas Malladi, et al.
International Journal of Surgical Pathology|August 3, 2016
Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In SituGary Tozbikian, Edi Brogi, Christina E Vallejo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-upLee K Tan, Dilip Giri, Amanda J Hummer, et al.
Histopathology|August 26, 2020
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelineRaza S Hoda, Anita S Bowman, Ahmet Zehir, et al.
Archives of Pathology & Laboratory Medicine|October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0Raza S Hoda, Edi Brogi, Jin Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2003
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumorsPaola de Candia, David B Solit, Dilip Giri, et al.
Breast Cancer Research and Treatment|December 9, 2016
Estimating the OncotypeDX score: validation of an inexpensive estimation toolAnne A Eaton, Catherine E Pesce, James O Murphy, et al.
Pageof 22

Showing results (91-100 of 214) with videos related to

Sort By:
Pageof 22
Cancer|March 26, 2003
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutationsNoah D Kauff, Edi Brogi, Lauren Scheuer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 14, 2021
Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scannersAbeer M Salama, Matthew G Hanna, Dilip Giri, et al.
Cancer Research|May 19, 2006
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanismKotha Subbaramaiah, Louise R Howe, Elisa R Port, et al.
Cell|September 3, 2013
Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stromaXiang H-F Zhang, Xin Jin, Srinivas Malladi, et al.
International Journal of Surgical Pathology|August 3, 2016
Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In SituGary Tozbikian, Edi Brogi, Christina E Vallejo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-upLee K Tan, Dilip Giri, Amanda J Hummer, et al.
Histopathology|August 26, 2020
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guidelineRaza S Hoda, Anita S Bowman, Ahmet Zehir, et al.
Archives of Pathology & Laboratory Medicine|October 25, 2019
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With <i>HER2</i>/CEP17 Ratio <2.0 and Average <i>HER2</i> Copy Number ≥4.0 and <6.0Raza S Hoda, Edi Brogi, Jin Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2003
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumorsPaola de Candia, David B Solit, Dilip Giri, et al.
Breast Cancer Research and Treatment|December 9, 2016
Estimating the OncotypeDX score: validation of an inexpensive estimation toolAnne A Eaton, Catherine E Pesce, James O Murphy, et al.
Pageof 22